TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06349928

Intervention type: OTHER
Intervention: Focus group or interview
Description: Focus groups and qualitative interview will be conducted with dancers investigating thoughts, beliefs and behaviors related to injury. Individual interviews (in presence or online) will be hold as alternative if it will not be possible (due to logistical or personal problems) to participate in a focus group or if the number of people who would have agreed to participate in that focus group is less than 3
Study: NCT06161168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bootle Blast Play Phase (B)
Description: Bootle Blast will be trialed for 14 weeks in the homes of 60 young people (6 to 17 years) with any motor condition that could be addressed by the Bootle Blast system, regardless of their diagnosis. The investigators will assess feasibility (e.g. independent home setup, ability to set/meet self-directed play time goals), enablers/barriers to use, and perceived value.~During the 8-week intervention phase (B), children will have Bootle Blast at home and play it according to their family-directed playtime goals. Weekly logs of therapy activities and problems encountered while playing will be collected through survey links. Additionally, families will record a video of their child performing the tasks associated with their COPM goals on a weekly basis. After the 8-week intervention (B) phase, participants will enter a second 3-week baseline (A) phase, during which they'll be asked to stop playing Bootle Blast, and the game will be programmatically locked to prevent further play.
Study: NCT06266884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo care
Description: Kangaroo care is a safe and effective method in which the baby is placed in an upright position on the parent's bare chest, wearing only a diaper and a hat, and the baby's needs for nutrition, warmth, love and trust are met and provides positive interaction between the parent and the baby.
Study: NCT06375707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: physician's choice of chemotherapy sequential Ribociclib combined with NSAI±OFS
Description: Docetaxel: 100mg/m2 IV every 21 days Paclitaxel: 175mg/m2 every 21 days, IV drip Vinorelbine: 25mg/ m2 on days 1 and 8 of each cycle, 1 cycle in 21 days, IV drip Capecitabine: 1000mg/m2, 2 times/d, 2 consecutive weeks of oral discontinuation for 1 week.~Ribociclib: 600mg /d, 3 weeks continuous oral withdrawal for 1 week NSAI: Anastrozole 1mg, 1 time /d, oral or Letrozole: 2.5mg, 1 time /d, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib combined with NSAI±OFS
Description: Ribociclib: 600mg /d, 3 weeks continuous oral withdrawal for 1 week NSAI: Anastrozole 1mg, 1 time /d, oral or Letrozole: 2.5mg, 1 time /d, oral
Study: NCT05190718

Intervention type: DEVICE
Intervention: Pharyngeal electrostimulation
Description: Routine treatment:~Pharyngeal stimulation is performed via a nasogastric probe (Phagenyx) for a duration of 10 minutes daily and for at least 3 consecutive days. The number of stimulation repeats until max 2x3 repeats, depends on therapy progress and an interdisciplinary re-evaluation of the patient's rehabilitation potential.
Study: NCT05140941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet
Description: One Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet taken once daily for 84 days.
Study: NCT06185361

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine 20 MG
Description: fluoxetine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmopressin
Description: desmopressin
Study: NCT05584267

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Different cohorts received different doses of radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Different cohorts received different doses of radiotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy + immunotherapy
Description: Chemotherapy + immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy + immunotherapy
Description: Chemotherapy + immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy + immunotherapy
Description: Chemotherapy + immunotherapy
Study: NCT05629481

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fractional carbon dioxide laser treatment
Description: Participants underwent three vaginal fractional CO2 laser (AcuPulse, Lumenis, Yokneam Illit, Israel) treatment sessions with 4-6 weeks intervals. The same laser device parameters (10 mJ, 10% density, spot diameter of 12×12 mm2) were used in participants. A special laser probe was inserted into the patient's vagina after cleaning and disinfection. The laser procedure was performed at the 0, 2, 4, 6, 8, and 10 o'clock positions by rotating the laser probe from the proximal vagina to the distal, and additional procedures were performed at the 11 and 1 o'clock positions 5 mm above the introitus vaginae.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Fractional carbon dioxide laser sham treatment
Description: Participants underwent three vaginal fractional CO2 laser (AcuPulse, Lumenis, Yokneam Illit, Israel) sham treatment sessions with 4-6 weeks intervals. A special laser probe was inserted into the patient's vagina after cleaning and disinfection. The sham procedure was performed at the 0, 2, 4, 6, 8, and 10 o'clock positions by rotating the laser probe from the proximal vagina to the distal, and additional sham procedures were performed at the 11 and 1 o'clock positions 5 mm above the introitus vaginae.
Study: NCT05657483

Intervention type: DIAGNOSTIC_TEST
Intervention: Venous blood sample
Description: Blood chemistry tests: neutrophil; lymphocyte; monocyte; platelet counts.

Intervention type: OTHER
Intervention: Surgical staging of endometrial cancer
Description: Endometrial, adnexal, and lymphoid tissue samples.
Study: NCT06116838

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal motor evoked responses (sMERs)
Description: Spinally Evoked Motor Responses (sMERs) will be obtained while stimulating with single pulses using various stimulation parameters. sMERs are the electromyograph (EMG) responses of the peripheral muscles to electrical stimulation of the spinal cord. sEMP will be used to test the integrity of the motor pathways of the spinal cord. This will be measuring by assessing the EMG responses in the lower limb muscles.
Study: NCT05365048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local Tailoring implementation strategy
Description: The local-tailored approach will be guided by a structured process involving the following: (1) convening a local HPV vaccine project team, (2) conducting a local diagnostic process to identify top barriers, (3) selecting from a menu of intervention options that will be offered in this study, categorized by core function (i.e., the forms and functions menu) that address top local barriers, and (4) deploying the selected interventions. The barrier assessment and intervention customization are key processes for the local-tailored strategy, which allow clinics to devote resources to respond to unique local barriers in addition to common barriers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prescribed Strategy
Description: The prescribed strategy is the standard implementation approach used by most health systems. Our prescribed approach will be guided by the evidence-based, award-winning 4 Pillars™ Practice Transformation Program for improving vaccination rates in the outpatient setting. The 4 Pillars™ address 4 main functions, i.e., convenience, communication, office systems, and motivation to guide the selection of interventions. For adolescent HPV vaccination, the 4 Pillars has demonstrated moderate effectiveness.
Study: NCT06116838

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal motor evoked responses (sMERs)
Description: Spinally Evoked Motor Responses (sMERs) will be obtained while stimulating with single pulses using various stimulation parameters. sMERs are the electromyograph (EMG) responses of the peripheral muscles to electrical stimulation of the spinal cord. sEMP will be used to test the integrity of the motor pathways of the spinal cord. This will be measuring by assessing the EMG responses in the lower limb muscles.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous stimulation tolerance
Description: Participants may receive up to 45 min of locomotion training (treadmill or overground training) with transcutaneous spinal cord stimulation. The goal will be for the investigators to determine what amount of intensity at each stimulation site the individual finds to be comfortable enough that they would be able to receive without pain or discomfort

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous stimulation tolerance
Description: Participants may receive up to 45 min of locomotion training (treadmill or overground training) with transcutaneous spinal cord stimulation. The goal will be for the investigators to determine what amount of intensity at each stimulation site the individual finds to be comfortable enough that they would be able to receive without pain or discomfort
Study: NCT06070064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effect of music on the manifestation of strength
Description: After the first 1RM visit, described above, each participant will complete 2 additional randomised, counterbalanced visits, each with one condition: Music (MUS) and No Music (No-MUS). The participants will be instructed to attend the laboratory to perform the screening test in different environmental conditions that do not impact on their health status.~During the MUS session, participants will perform a back squat test and a CJM test while listening to music. The chosen songs will be at least 120 beats per minute (BPM) 15. The tempo of the music for each of the tracks will be calculated using bpm software (Tangerine!v.1.4). The music will be played using an iPhone X (Apple Inc., Cupertino, CA, USA) connected to a portable speaker (Sony MHC-V02, Sony Co., Tokyo, Japan). The sound intensity will be adjusted and standardised for all participants to 75 dB (at ear level) using the Decibel X-dBA sound level meter. Trap and reggaeton music will be played before, during and after the test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effect of music on the manifestation of strength
Description: After the first 1RM visit, described above, each participant will complete 2 additional randomised, counterbalanced visits, each with one condition: Music (MUS) and No Music (No-MUS). The participants will be instructed to attend the laboratory to perform the screening test in different environmental conditions that do not impact on their health status.~During the MUS session, participants will perform a back squat test and a CJM test while listening to music. The chosen songs will be at least 120 beats per minute (BPM) 15. The tempo of the music for each of the tracks will be calculated using bpm software (Tangerine!v.1.4). The music will be played using an iPhone X (Apple Inc., Cupertino, CA, USA) connected to a portable speaker (Sony MHC-V02, Sony Co., Tokyo, Japan). The sound intensity will be adjusted and standardised for all participants to 75 dB (at ear level) using the Decibel X-dBA sound level meter. Trap and reggaeton music will be played before, during and after the test.
Study: NCT04562389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Participants will receive a dose of 40 or 60 mg selinexor oral tablets QW.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Participants will receive a dose of 40 or 60 mg selinexor oral tablets QW.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Participants will receive a dose of 40 or 60 mg selinexor oral tablets QW.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Participants will receive a dose of 60 mg selinexor oral tablets QW.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive a matching placebo of selinexor oral tablets QW

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Participants will receive a dose of 15 or 20 mg ruxolitinib oral tablets BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Participants will receive a dose of 15 or 20 mg ruxolitinib oral tablets BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Participants will receive a dose of 15 or 20 mg ruxolitinib oral tablets BID.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ruxolitinib
Description: Participants will receive a dose of 15 or 20 mg ruxolitinib oral tablets BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Participants will receive a dose of 15 or 20 mg ruxolitinib oral tablets BID.
Study: NCT05451498

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: Participants were matched according to fat-free mass to consume a placebo, or 5-g dose of creatine monohydrate within one hour before training, or within one hour after training for 8 weeks while completing a weekly resistance training program. At each time point (before and after training), all participants co-ingested a 25-gram dose whey isolate and a 25-gram dose of carbohydrate powder along with their assigned supplement. Body composition using a 3-compartment field (3CFIELD), muscular strength (one-repetition maximum \[1RM\]) and endurance (repetitions to fatigue \[RTF\] at 80% 1RM) using bench press (BP) and back squat (SQ) exercises along with isometric mid-thigh pull (IMTP) were assessed before and after the 8-week supplementation period.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: Participants were matched according to fat-free mass to consume a placebo, or 5-g dose of creatine monohydrate within one hour before training, or within one hour after training for 8 weeks while completing a weekly resistance training program. At each time point (before and after training), all participants co-ingested a 25-gram dose whey isolate and a 25-gram dose of carbohydrate powder along with their assigned supplement. Body composition using a 3-compartment field (3CFIELD), muscular strength (one-repetition maximum \[1RM\]) and endurance (repetitions to fatigue \[RTF\] at 80% 1RM) using bench press (BP) and back squat (SQ) exercises along with isometric mid-thigh pull (IMTP) were assessed before and after the 8-week supplementation period.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Participants were matched according to fat-free mass to consume a placebo (maltodextrin) within one hour before training, or within one hour after training for 8 weeks while completing a weekly resistance training program. At each time point (before and after training), all participants co-ingested a 25-gram dose whey isolate and a 25-gram dose of carbohydrate powder along with their assigned supplement. Body composition using a 3-compartment field (3CFIELD), muscular strength (one-repetition maximum \[1RM\]) and endurance (repetitions to fatigue \[RTF\] at 80% 1RM) using bench press (BP) and back squat (SQ) exercises along with isometric mid-thigh pull (IMTP) were assessed before and after the 8-week supplementation period.
Study: NCT05677152

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Infusion of Aclasta®
Description: Intravenous Infusion of Aclasta® (Verum) or physiological saline solution 0.9% (Placebo)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Infusion of Aclasta®
Description: Intravenous Infusion of Aclasta® (Verum) or physiological saline solution 0.9% (Placebo)
Study: NCT05001594

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active vibratory knee device
Description: The active, wearable device is placed above and below the knee joint. The device consists of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide vibratory feedback to the subject.
Study: NCT04789512

Intervention type: OTHER
Intervention: Respiratory functions
Description: Respiratory muscle strength, pulmonary functions and body composition were evaluated in volleyball players

Intervention type: OTHER
Intervention: Respiratory functions
Description: Respiratory muscle strength, pulmonary functions and body composition were evaluated in volleyball players
Study: NCT05877378

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single-use negative pressure therapy (PICO)
Description: PICO system will be applied to patients in the intervention group with diabetic foot ulcers, venous leg ulcers or pressure ulcers. This device will be changed every 7 days, until the wound is closed, or until a set period of study duration, approximately 12 weeks.
Study: NCT06249373

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low intensity pulse ultrasound （LIPUS） intervention for arteriovenous fistula anastomosis
Description: The LIPUS intervention group for arteriovenous fistula should receive forearm wearable portable low-intensity pulse ultrasound （LIPUS） intervention at the anastomotic site no more than 3 days after suture removal two weeks after the fistula surgery. If the ultrasound examination indicates the presence of stenosis in the outflow tract, the intervention should also be performed at the same time. It belongs to non-invasive extracorporeal intervention, with three times a week （during dialysis） for 20 minutes each time. The sound intensity is 350mW/cm2, the pulse frequency is 1MHz, the pulse repetition frequency is 100Hz, the pulse frequency is 100 times, and the treatment period is 12 weeks.
Study: NCT06370260

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrogen Carbamide/Peroxide Gel
Description: UNISEPT® ORAL GEL is an oral gel containing 10% w/v urea peroxide which releases 3.50% w/w hydrogen peroxide, glycerin, propylene glycol, carbopol, disodium EDTA, sodium saccharin, methyl salicylate, menthol, and water, serving as the active ingredient.~Participants should apply the gel to the biopsy area and the corresponding sextant teeth three times daily, leaving it on for five minutes without rinsing, for a total of 14 days, beginning on day 0., i.e. the day of the biopsy (see procedure in the detailed description). Consumption of liquid or solid foods should be avoided for at least thirty minutes following gel application.Participants are asked to maintain their usual oral hygiene routine.~UNISEPT® ORAL GEL is a Class IIa, CE-marked medical device made and distributed by Intermed S.A. and Ioulia And Irene Tseti Pharmaceutical Laboratories S.A.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: Placebo gel is a similar (look-and-taste-alike) product to UNISEPT® ORAL GEL, made by the same manufacturer, without active ingredients, containing glycerin, propylene glycol, carbomer, menthol, sodium saccharin, methyl salicylate, triethanolamine.~Participants are called upon to apply the gel in exactly the same way as the experimental product, i.e apply the gel to the biopsy area and the corresponding sextant teeth three times daily, leaving it on for five minutes without rinsing, for a total of 14 days, beginning on day 0.
Study: NCT05150496

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated
Description: Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated: 600SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
Study: NCT05036863

Intervention type: BEHAVIORAL
Intervention: Weekly questionnaires
Description: Patients will complete weekly symptom monitoring PROMs. If a symptom exceeds the thresholds for clinical importance, a registered nurse will contact the patient, confirm the symptoms and coordinate the further clinical procedure in line with standard practice.
Study: NCT05150496

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated
Description: Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated: 600SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dose COVID-19 Vaccine(Vero Cell),Inactivated
Description: High-dose COVID-19 Vaccine(Vero Cell),Inactivated:1200SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dose COVID-19 Vaccine(Vero Cell),Inactivated
Description: High-dose COVID-19 Vaccine(Vero Cell),Inactivated:1200SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
Study: NCT06608316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta Burst Stimulation
Description: A novel transcranial magnetic stimulation protocol called intermittent theta pulse stimulation (iTBS) effectively mimics the brain's naturally occurring theta rhythms and promotes significant synaptic changes. Compared to traditional stimulation methods, iTBS is more effective at initiating long-term potential (LTP) and produces significant excitatory effects in a shorter period of time.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta Burst Stimulation
Description: A novel transcranial magnetic stimulation protocol called intermittent theta pulse stimulation (iTBS) effectively mimics the brain's naturally occurring theta rhythms and promotes significant synaptic changes. Compared to traditional stimulation methods, iTBS is more effective at initiating long-term potential (LTP) and produces significant excitatory effects in a shorter period of time.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intermittent Theta Burst Stimulation
Description: A novel transcranial magnetic stimulation protocol called intermittent theta pulse stimulation (iTBS) effectively mimics the brain's naturally occurring theta rhythms and promotes significant synaptic changes. Compared to traditional stimulation methods, iTBS is more effective at initiating long-term potential (LTP) and produces significant excitatory effects in a shorter period of time.
Study: NCT06610110

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Acute caffeine intake (3 mg/kg)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Acute caffeine intake (3 mg/kg)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Acute caffeine intake (3 mg/kg)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Acute caffeine intake (3 mg/kg)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (3 mg/kg maltodextrin)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (3 mg/kg maltodextrin)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (3 mg/kg maltodextrin)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (3 mg/kg maltodextrin)